Seeking Alpha

Cubist to acquire Trius, Optimer

  • Cubist Pharmaceuticals (CBST) says it will acquire Trius Therapeutics (TSRX) for $13.50/ share plus CVRs worth $2/ share. (PR)
  • CBST will also buy Optimer Pharmaceuticals (OPTR) for $10.75/ share plus CVRs worth $5/ share tied to Dificid sales milestones. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector